Literature DB >> 20002154

Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.

Domenica Caramazza1, Kebede Hussein, Sergio Siragusa, Animesh Pardanani, Ryan A Knudson, Rhett P Ketterling, Ayalew Tefferi.   

Abstract

Chromosome 1 is the largest human chromosome and contains over 1600 known genes and 1000 novel coding sequences or transcripts. It is, therefore, not surprising that recurrent chromosome 1 abnormalities are regularly encountered in both neoplastic and non-neoplastic medical conditions. The current review is focused on myeloid malignancies where we summarize the relevant published literature and discuss specific karyotype-phenotype associations. We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Specific abnormalities include duplications (e.g. 1q12-->1q32 in PV, 1q21-32-->1q32-44 in post-PV MF or PMF), deletions (e.g. 1p13-36-->pter in PV or PMF, 1q21 in PMF) and unbalanced translocations involving chromosome 6, such as der(6)t(1;6)(q21-25;p21.3-23), and other partner chromosomes involving 1q10/1p11 and 1q21-25 breakpoints. Although occasionally seen in chronic phase MPN, unbalanced 1;7 translocations, e.g. der(1;7)(q10;p10), are usually seen in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and post-MPN AML/MDS. These observations suggest that certain chromosome 1 regions, especially 1q21-1q32 and 1p11-13, might harbor oncogenes or tumor suppressor genes that are pathogenetically relevant to both chronic and advanced phases of MPN.

Entities:  

Mesh:

Year:  2009        PMID: 20002154     DOI: 10.1111/j.1600-0609.2009.01392.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  12 in total

Review 1.  Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

Authors:  Syed J Noor; Wei Tan; Gregory E Wilding; Laurie A Ford; Maurice Barcos; Sheila N J Sait; Annemarie W Block; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-08-19       Impact factor: 3.156

2.  A case of myelodysplastic syndrome with a der(1;18)(q10;q10) translocation.

Authors:  Jung-Sook Ha; Dong-Suk Jeon
Journal:  Blood Res       Date:  2014-06-25

3.  A rare der(Y)t(Y;1)(q12;q12) in a patient with post-polycythemic myelofibrosis: a case report.

Authors:  Masahiro Manabe; Osami Takeda; Junya Okita; Teruhito Takakuwa; Naonori Harada; Hirofumi Nakano; Shuichiro Okamoto; Yasutaka Aoyama; Takeo Kumura; Tadanobu Ohta; Yoshio Furukawa; Atsuko Mugitani
Journal:  Am J Blood Res       Date:  2013-05-05

Review 4.  Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.

Authors:  Nisha R Singh
Journal:  Transl Pediatr       Date:  2015-04

Review 5.  Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Authors:  Francesco Passamonti; Barbara Mora; Daniela Barraco; Margherita Maffioli
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

6.  Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer.

Authors:  Deniz Abat; Osman Demirhan; Nihal Inandiklioglu; Erdal Tunc; Seyda Erdogan; Deniz Tastemir; Inayet Nur Uslu; Zuhtu Tansug
Journal:  Oncol Lett       Date:  2014-05-02       Impact factor: 2.967

7.  A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer.

Authors:  Garima Sharma; Pradeep Dua; Subhash Mohan Agarwal
Journal:  Curr Genomics       Date:  2014-08       Impact factor: 2.236

8.  [Clinical and cytogenetic study of chromosome 1 abnormality in myelodysplastic syndrome].

Authors:  Wei Wang; Zhimei Chen; Mengxia Yu; Huanping Wang; Jiyu Lou; Huan Xu; Chao Hu; Qitian Mu; Hongyan Tong; Juying Wei; Xinping Zhou; Jie Jin
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10

9.  Polyploidy in myelofibrosis: analysis by cytogenetic and SNP array indicates association with advancing disease.

Authors:  Nisha R Singh; Christine M Morris; Mary Koleth; Kelly Wong; Christopher M Ward; William S Stevenson
Journal:  Mol Cytogenet       Date:  2013-12-17       Impact factor: 2.009

10.  tRNA synthetase counteracts c-Myc to develop functional vasculature.

Authors:  Yi Shi; Xiaoling Xu; Qian Zhang; Guangsen Fu; Zhongying Mo; George S Wang; Shuji Kishi; Xiang-Lei Yang
Journal:  Elife       Date:  2014-06-17       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.